transcribed from fax received on 06/16/21
pdf – http://vpwas.com/skm_c224e21062210410/
Date: June 15, 2021
Bristol Myers Squibb would like to inform you that the sale and distribution of Sustiva® (efavrinz) will be discontinued in Canada. Sustiva® (efavrinz)is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. This discontinuation includes tablet (600mg) formulation on September 30, 2022 and capsule (50mg and 200mg) formulation on March 31, 2023.
The decision to discontinue Sustiva is voluntary and not related to any quality, safety or efficacy issues regarding the product. the usage of Sustiva has been declining over the past years because of the availability of advanced antiretroviral tharapies and efavrinz generics tablet formulations for treatment of HIV infection. Some of the other advanced therapies are now considered first choice options and efavrinz is no longer recommended as preferred or a first-line regimen for HIV-1 treatment in adults, pregnant women, adolescents and pediatric patients.
If you have questions or require additional information regarding the discontinuation, please contact Bristol Myers Squibb at 1.800.267.0005 or via email at otc.canada@bms.com.
For medical requests, please contact our Medical information Services at 1.866.463.6267 or at medical.canada@bms.com
